Solid Tumors with Specific Mutations

- **IDH 1/2 mutant**
  - 10129: A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
  - 10222: Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH)-Mutant Solid Tumors

- **CCNE1 amplification**
  - 10221: Phase I/II Biomarker-Driven Combination Trial of Copanlisib and Immune Checkpoint Inhibitors in Patients with Advanced Solid Tumors
  - 10136: A Phase 2 Trial of AZD1775, a Wee1 Inhibitor, in Patients with CCNE1 Amplification

- **PTEN, PIK3CA**
  - 9149: Molecular Profiling-Based Assignment of Cancer Therapy for Patients with Advanced Solid Tumors
  - 10131: Phase I Study of AZD8186 in Combination with Docetaxel in Patients with PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel (Expansion: breast, prostate, other solid tumors)

- **DNA repair; PI3K/AKT; RAS/RAF/MEK**
  - 10217: A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors (Expansion: germline or and somatic DDR aberrations; PIK3CA mutant; PTEN loss)
  - 10170: A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies

- **NF1, KEAP1, and LKB1**
  - 10220: A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients with NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors

- **Loss of SETD2**
  - 10329: Phase I Sequential Trial of Agents Against DNA Repair (STAR) (Dose escalation: enriched for DDR aberrations; Expansion: Cohort A: BRCA1/2; Cohort B: DDR aberrations)

- **NUT fusion oncogene**
  - 10295: A Phase 1/2 Study of the Bromodomain Inhibitor Molibresib in Combination with Etoposide/Platinum in Patients with NUT Carcinoma

- **HER2-positive**
  - 10346: A Phase I Study of DS-8201a Pharmacodynamics in Patients with HER2-positive Advanced Solid Tumors

**NOTE:** * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: August 23, 2019